BioLegend Acquires the Antibody Products Business Unit from Covance

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014. The Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection. These products, including In Vitro Diagnostic (IVD) antibodies for IHC, are well-suited to complement and enhance the current selection of BioLegend research reagents. Covance Antibody customers can expect the same superior customer support and exceptional value with these products as existing BioLegend customers.
SAN DIEGO, (informazione.it - comunicati stampa - salute e benessere)

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014. The Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection. These products, including In Vitro Diagnostic (IVD) antibodies for IHC, are well-suited to complement and enhance the current selection of BioLegend research reagents. Covance Antibody customers can expect the same superior customer support and exceptional value with these products as existing BioLegend customers.

Photo - http://photos.prnewswire.com/prnh/20140825/139472

"We are excited to add Covance Antibody's people and products to the BioLegend team," said Gene Lay, President and CEO, BioLegend. As neuroinflammation and neurodegeneration become increasingly important topics, Covance Antibody is an ideal strategic fit in BioLegend's commitment to the advancement of discovery in neuroscience. With the addition of a world-class R&D team and over 600 antibody products for emerging and important targets in this field, BioLegend is positioned to become a leader in neuroscience and immunology research.

BioLegend Acquires the Antibody Products Business Unit from Covance

"The addition of Neuroscience and IHC antibody tools to our catalog means accelerated discovery for our current and new customers. We also hope to bring our well-known quality, support, and value in the Immunology community to Neuroscience researchers world-wide," said Gene Lay.

To learn more, visit: biolegend.com/covance_antibody_acquisition.

About BioLegend:

BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend headquarters in San Diego, CA operates under an ISO 9001:2008 and ISO 13485:2003 certified quality management system. For more information on BioLegend, visit: http://www.biolegend.com

Per maggiori informazioni
Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili